A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study)

医学 止吐药 化疗引起恶心呕吐 恶心 奥氮平 呕吐 消炎药 安慰剂 化疗 干呕 养生 昂丹司琼 临床终点 化疗方案 麻醉 内科学 随机对照试验 精神科 精神分裂症(面向对象编程) 替代医学 病理
作者
Yuanyuan Zhao,Yunpeng Yang,Fangfang Gao,Chang-Lu Hu,Diansheng Zhong,Miaozhen Lu,Zhiping Yuan,Jianqing Zhao,Jidong Miao,Yán Li,Jie Zhu,Chunbin Wang,Jianjun Han,Yanqiu Zhao,Yan Huang,Li Zhang
出处
期刊:EClinicalMedicine [Elsevier BV]
卷期号:55: 101771-101771 被引量:23
标识
DOI:10.1016/j.eclinm.2022.101771
摘要

BackgroundEvidence supports prophylactic use of olanzapine for the treatment of chemotherapy-induced nausea and vomiting (CINV). However, most studies to date have focused on patients with single-day highly emetogenic chemotherapy (HEC). Currently, administration of antiemetic therapies for nausea and vomiting induced by multiday chemotherapy regimens remains a challenge. In this study, we evaluated the efficacy of olanzapine combined with triple antiemetic therapy for the prevention of CINV in patients receiving multiday chemotherapy.MethodsWe performed a randomized, double-blind, placebo-controlled phase 3 trial in 22 hospitals. Eligible patients were between 18 and 75 years old, were diagnosed with malignant solid tumors, and they had an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2. All the study participants were scheduled to be treated with chemotherapy regimens containing 3-day cisplatin (3-day total dose ≥75 mg/m2). Randomization was computer generated and stratified by gender and chemotherapy treatment history. Allocation was done via an interactive web response system. Enrolled patients were randomly assigned 1:1 to receive either 5 mg olanzapine or placebo orally before bedtime for 5 days combined with intravenous fosaprepitant (150 mg) 1 h before the administration of cisplatin on day 1, ondansetron hydrochloride intravenously, and dexamethasone orally 30 min before cisplatin from days 1 to 3. Dexamethasone was also administered at the same time on days 4 and 5. The primary endpoint was the proportion of subjects with complete response (no vomiting and no rescue therapy) within the overall phase (days 1–8) after starting chemotherapy. Baseline plasma concentrations of P-substance and 5-HT were measured for exploratory analysis. This study was registered at ClinicalTrials.gov, number NCT04536558.FindingsBetween December 2020 and September 2021, 349 patients with malignant solid tumors were enrolled in the study, with 175 participants randomly assigned to receive olanzapine and 174 participants assigned to receive placebo. The proportion of patients who achieved a complete response in the overall phase was significantly higher in the olanzapine group than in the placebo group (69% vs. 58%, P = 0.031). A complete response benefit was observed in the olanzapine group versus the placebo group in almost all the subgroups. Four factors were considered significantly associated with complete response in multivariable analysis: treatment group, gender, baseline plasma concentration of 5-HT, and prior radiotherapy. All the reported adverse events associated with olanzapine administration were grades 1 and 2.InterpretationOlanzapine (5 mg) combined with fosaprepitant, ondansetron, and dexamethasone was better than triple antiemetic therapy alone for patients receiving multiday chemotherapy regimens. Based on these results, the four-drug combination should be recommended as the best antiemetic regimen given to patients receiving multiday cisplatin-based chemotherapy and baseline plasma concentration of 5-HT may be used to identify individuals who are prone to CINV. However, all these findings need to be further validated in future studies.FundingJiangsu Hansoh Pharmaceutical Group Co., Ltd. provided research grant and study drugs for this investigator-initiated study.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
悦悦完成签到,获得积分10
刚刚
neurospine发布了新的文献求助10
刚刚
li发布了新的文献求助10
1秒前
3秒前
4秒前
远了个方发布了新的文献求助10
4秒前
5秒前
远了个方发布了新的文献求助10
5秒前
远了个方发布了新的文献求助10
5秒前
5秒前
李爱国的应助被外向烨磊采纳,获得10
6秒前
Jasper的应助被DYY采纳,获得10
6秒前
隐形曼青的应助被neurospine采纳,获得10
7秒前
FashionBoy的应助被Liam采纳,获得10
8秒前
9秒前
李健的小迷弟的应助被taik采纳,获得10
9秒前
整齐芷文完成签到,获得积分10
10秒前
Justin完成签到,获得积分10
11秒前
夏夏发布了新的文献求助10
12秒前
12秒前
cube发布了新的文献求助10
14秒前
xz完成签到,获得积分10
16秒前
16秒前
16秒前
neurospine完成签到,获得积分10
16秒前
16秒前
远了个方发布了新的文献求助10
17秒前
司藤完成签到 ,获得积分0
18秒前
18秒前
19秒前
20秒前
Chen发布了新的文献求助10
21秒前
23秒前
ZX发布了新的文献求助10
23秒前
23秒前
24秒前
24秒前
25秒前
25秒前
风清扬的应助被tantan采纳,获得10
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192903
求助须知:如何正确求助?哪些是违规求助? 9579346
关于积分的说明 21864636
捐赠科研通 7792529
什么是DOI,文献DOI怎么找? 3437107
关于科研通互助平台的介绍 2560653
邀请新用户注册赠送积分活动 2483937